NR4A1 and endometrial cancer: Also, the combination of PI3K/AKT inhibitors with hormonal therapies, such as progesterone or aromatase inhibitors (such as exemestane), may synergistically inhibit tumor growth and enhance response rates in hormone-receptor-positive endometrial cancers [47,141,142].